By Maggie Fick

LONDON (Reuters) -AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients at a discount of up to 70% off list prices, the latest pharma company to do so after pressure from U.S. President Donald Trump.

The Anglo-Swedish company, Britain’s biggest by market value, said uninsured or underinsured patients with prescriptions will be able to buy their Farxiga treatment for diabetes for $182 starting October 1.

That is the same price as Medicare and Medicaid patients will pay from January 1 next year, AstraZeneca said, and is 70% below the list price.

Asthma drug Airsupra will be sold for $249, about 50% below the list price, the company said.

Patients will also be able to order the nasal spray flu vaccine FluMist from the new

See Full Page